Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

avanafil

Known as: (S)-4-(3-Chloro-4-methoxybenzylamino)-2-(2-hydroxymethylpyrrolidin-1-yl)-N-pyrimidin-2-ylmethyl-5-pyrimidinecarboxamide, 4-((3-chloro-4-methoxybenzyl)amino)-2-(2-(hydroxymethyl)-1-pyrrolidinyl)-N-(2-pyrimidinylmethyl)-5-pyrimidinecarboxamide 
An orally available phosphodiesterase type 5 (PDE5) inhibitor with vasodilatory activity. Avanafil selectively inhibits PDE5, thus inhibiting the… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2017
Highly Cited
2017
Mitochondrial DNA (mtDNA) mutations frequently cause neurological diseases. Modeling of these defects has been difficult because… Expand
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2014
2014
Utilization of lipid-based drug delivery systems has recently gained focus for drugs characterized by poor aqueous solubility… Expand
  • table I
  • figure 1
  • figure 2
  • figure 3
  • table II
Is this relevant?
Highly Cited
2013
Highly Cited
2013
PURPOSE We evaluated the safety and efficacy of 100 and 200 mg avanafil for the treatment of adult males with erectile… Expand
Is this relevant?
Review
2013
Review
2013
Introduction: Phosphodiesterase type 5 inhibitors (PDE5-i) are used for the oral treatment of erectile dysfunction (ED). Since… Expand
Is this relevant?
Review
2013
Review
2013
Orally active, selective inhibitors of phosphodiesterase type 5 (PDE 5, cyclic GMP PDE), such as sildenafil, tadalafil and… Expand
  • figure 1
Is this relevant?
Highly Cited
2012
Highly Cited
2012
INTRODUCTION Phosphodiesterase type 5 (PDE5) inhibitors have become standard treatment for erectile dysfunction (ED). AIM To… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 5
  • table 3
Is this relevant?
2012
2012
OBJECTIVE To prospectively assess the safety and effectiveness of the investigational phosphodiesterase 5 inhibitor avanafil to… Expand
Is this relevant?
2012
2012
PURPOSE We investigated the in vitro inhibitory effects of avanafil, a novel, potent inhibitor of phosphodiesterase-5, on 11… Expand
Is this relevant?
2012
2012
UNLABELLED Study Type--Therapy (RCT) Level of Evidence 1b. What's known on the subject? and What does the study add? Avanafil is… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 4
  • table 2
Is this relevant?
2010
2010
BACKGROUND Avanafil is a selective phosphodiesterase type 5 inhibitor being developed for the treatment of erectile dysfunction… Expand
Is this relevant?